A Phase 1/2a, Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients with Advanced Solid Tumors and Lymphomas

Trial Profile

A Phase 1/2a, Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients with Advanced Solid Tumors and Lymphomas

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Belizatinib (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors TESARO
  • Most Recent Events

    • 18 Oct 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2017.
    • 18 Oct 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Sep 2016.
    • 04 Oct 2016 This trial was completed in Spain, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top